A U.S. House committee sent a letter to Mylan NV demanding a fuller explanation of why the company omitted key information it used to calculate the profit figure for the lifesaving EpiPen drug that its chief executive provided during a Congressional hearing last month.
from WSJ.com: US Business http://ift.tt/2dVrTIY
via IFTTT
No comments:
Post a Comment